Adverum Biotechnologies, Inc. (ADVM)

Adverum Biotechnologies Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019	2018 - 2012
Revenue	3.6	0	7.5	0	0.25	Upgrade
Revenue Growth (YoY)	-	-	-	-	-84.49%	Upgrade
Gross Profit	3.6	0	7.5	0	0.25	Upgrade
Selling, General & Admin	49.92	57.86	64.44	44.64	28.38	Upgrade
Research & Development	77.68	99.28	89.18	73.31	40.42	Upgrade
Operating Expenses	127.59	157.14	153.62	117.95	68.8	Upgrade
Operating Income	-123.99	-157.14	-146.12	-117.95	-68.55	Upgrade
Other Expense / Income	-5.75	-2.67	-0.58	-1.56	-4.06	Upgrade
Pretax Income	-118.24	-154.46	-145.54	-116.39	-64.49	Upgrade
Income Tax	-1.08	0.07	0	1.11	0	Upgrade
Net Income	-117.17	-154.54	-145.54	-117.51	-64.49	Upgrade
Shares Outstanding (Basic)	10	10	10	9	6	Upgrade
Shares Outstanding (Diluted)	10	10	10	9	6	Upgrade
Shares Change	1.58%	1.24%	15.14%	32.83%	4.44%	Upgrade
EPS (Basic)	-11.60	-15.60	-14.80	-13.80	-10.10	Upgrade
EPS (Diluted)	-11.60	-15.60	-14.80	-13.80	-10.10	Upgrade
Free Cash Flow	-91.71	-119.91	-122.95	-91.14	-68.42	Upgrade
Free Cash Flow Per Share	-9.10	-12.08	-12.54	-10.70	-10.67	Upgrade
Gross Margin	100.00%	-	100.00%	-	100.00%	Upgrade
Operating Margin	-3444.19%	-	-1948.29%	-	-27418.00%	Upgrade
Profit Margin	-3254.58%	-	-1940.53%	-	-25794.40%	Upgrade
Free Cash Flow Margin	-2547.50%	-	-1639.39%	-	-27366.80%	Upgrade
EBITDA	-99.57	-143.89	-140.9	-112.24	-62.91	Upgrade
EBITDA Margin	-2765.89%	-	-1878.60%	-	-25165.20%	Upgrade
Depreciation & Amortization	18.67	10.57	4.65	4.16	1.57	Upgrade
EBIT	-118.24	-154.46	-145.54	-116.39	-64.49	Upgrade
EBIT Margin	-3284.53%	-	-1940.53%	-	-25794.40%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).